Naloxone for Neuroprotection in Acute SCI

 

Author Year

Country

Research Design

PEDro

Sample Size

Methods Outcomes

Bracken et al. (1990)

USA

RCT

PEDro=10

N=487

Population: Age range=13-34 yr; Gender: not specified; Level of injury: not specified; Severity of injury: complete= 60%, incomplete=40%.

Treatment: Patients were randomized to receive either naloxone (25 mg/mL), methylprednisolone (MP; 62.5 mg/mL) or placebo. Both drugs were administered as a 15 minute loading dose followed by a 23 hr maintenance dose.

Outcome Measures:The following after 6 weeks and 6 months: motor function, sensory function (pinprick and light touch), adverse event outcomes.

Chronicity: Individuals were randomized to study groups within 12 hr of sustaining injury.

Overall Analysis:

  1. There were no significant improvements in motor function or sensory function in patients who received either naloxone or MP compared those who received placebo 6 weeks and 6 months after injury (p>0.05).
  2. There were no significant differences in adverse event outcomes during hospitalization between those who received naloxone, those who received MP, and those who received placebo (p>0.05).
top